Regulus Therapeutics Inc. (RGLS)’s Stock Is Sell After Reaching 52-Week Low

July 16, 2018 - By Palma Niemeyer

Regulus Therapeutics Inc. (NASDAQ:RGLS) Logo

Investors sentiment decreased to 1.11 in 2018 Q1. Its down 0.05, from 1.16 in 2017Q4. It fall, as 8 investors sold Regulus Therapeutics Inc. shares while 10 reduced holdings. 9 funds opened positions while 11 raised stakes. 50.71 million shares or 4.62% less from 53.17 million shares in 2017Q4 were reported.
Geode Capital Lc stated it has 483,951 shares or 0% of all its holdings. Nea Lc invested in 10.99M shares. National Bank Of Montreal Can accumulated 4,500 shares or 0% of the stock. Alpine Mngmt Ltd Liability holds 0% or 10,223 shares. Royal Bankshares Of Canada has 146,607 shares. The Illinois-based Drw has invested 0.01% in Regulus Therapeutics Inc. (NASDAQ:RGLS). South Dakota Council stated it has 1.78M shares. United Services Automobile Association accumulated 33,260 shares. Stratos Wealth Ptnrs Limited holds 4,000 shares or 0% of its portfolio. Wells Fargo And Mn reported 384,538 shares or 0% of all its holdings. Deutsche Comml Bank Ag has invested 0% of its portfolio in Regulus Therapeutics Inc. (NASDAQ:RGLS). 13,304 are held by Bourgeon Cap Limited Liability Corp. Bnp Paribas Arbitrage has invested 0% of its portfolio in Regulus Therapeutics Inc. (NASDAQ:RGLS). Northern Corporation holds 187,492 shares or 0% of its portfolio. Meeder Asset has invested 0% of its portfolio in Regulus Therapeutics Inc. (NASDAQ:RGLS).

The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) hit a new 52-week low and has $0.26 target or 9.00 % below today’s $0.29 share price. The 8 months bearish chart indicates high risk for the $29.97M company. The 1-year low was reported on Jul, 16 by Barchart.com. If the $0.26 price target is reached, the company will be worth $2.70M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 4.07% or $0.0122 during the last trading session, reaching $0.2873. About 492,867 shares traded or 6.83% up from the average. Regulus Therapeutics Inc. (NASDAQ:RGLS) has declined 45.33% since July 16, 2017 and is downtrending. It has underperformed by 57.90% the S&P500.

Analysts await Regulus Therapeutics Inc. (NASDAQ:RGLS) to report earnings on August, 7. They expect $-0.16 EPS, up 60.98 % or $0.25 from last year’s $-0.41 per share. After $-0.15 actual EPS reported by Regulus Therapeutics Inc. for the previous quarter, Wall Street now forecasts 6.67 % negative EPS growth.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

Among 5 analysts covering Regulus (NASDAQ:RGLS), 0 have Buy rating, 0 Sell and 5 Hold. Therefore 0 are positive. Regulus had 9 analyst reports since February 8, 2018 according to SRatingsIntel. FBR Capital maintained it with “Neutral” rating and $0.5 target in Friday, July 6 report. As per Monday, March 12, the company rating was maintained by Wedbush. Wedbush maintained the shares of RGLS in report on Thursday, February 8 with “Buy” rating. Wells Fargo maintained it with “Market Perform” rating and $1 target in Friday, July 6 report. The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) earned “Market Perform” rating by BMO Capital Markets on Thursday, March 8. The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) has “Buy” rating given on Thursday, May 17 by Wedbush. As per Tuesday, March 27, the company rating was initiated by FBR Capital. The company was downgraded on Tuesday, July 10 by Wedbush.

More important recent Regulus Therapeutics Inc. (NASDAQ:RGLS) news were published by: Seekingalpha.com which released: “Regulus -48.4% as it slashes 60% of workforce to stretch cash” on July 05, 2018, also Nasdaq.com published article titled: “Mid-Day Market Update: Crude Oil Up Over 1%; Black Box Shares Spike Higher”, Streetinsider.com published: “Pre-Open Movers 07/06: (BBOX) (BIIB) (RGSE) Higher; (RGLS) (GCI) (PSMT) Lower (more…)” on July 06, 2018. More interesting news about Regulus Therapeutics Inc. (NASDAQ:RGLS) was released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” with publication date: July 10, 2018.

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. The company has market cap of $29.97 million. The Company’s two lead product candidates, RG-012 and RGLS4326, are in clinical development. It currently has negative earnings. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.